Japan's Chuikyo criticizes FPMAJ's Rx pharmaceuticals pricing plan
Members of Japan's Chuikyo (the Central Social Insurance Medical Council), from both the payer and provider sides, have criticized a new proposal of National Health Insurance drug pricing which the Federation of Pharmaceutical Manufacturers Associations of Japan submitted at an agency hearing earlier this month.
Though the proposal retains some elements of the Price Notification Approval System the FPMAJ presented late last year (Marketletter December 17, 2007), it has now agreed to use the current NHI drug pricing rules noting that the evaluation of the new products under the present system was improved in the drug price revision of April 2008, according to Akira Nagano, a member of the NHI Drug Pricing Expert Subcommittee of the Chuikyo, and an executive of Daiichi Sankyo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze